ZA201604490B - S1p3 antagonists - Google Patents
S1p3 antagonistsInfo
- Publication number
- ZA201604490B ZA201604490B ZA201604490A ZA201604490A ZA201604490B ZA 201604490 B ZA201604490 B ZA 201604490B ZA 201604490 A ZA201604490 A ZA 201604490A ZA 201604490 A ZA201604490 A ZA 201604490A ZA 201604490 B ZA201604490 B ZA 201604490B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195372.1A EP2878339A1 (en) | 2013-12-02 | 2013-12-02 | SIP3 antagonists |
| PCT/EP2014/075986 WO2015082357A1 (en) | 2013-12-02 | 2014-11-28 | S1p3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201604490B true ZA201604490B (en) | 2019-11-27 |
Family
ID=49674243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201604490A ZA201604490B (en) | 2013-12-02 | 2016-07-01 | S1p3 antagonists |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9951017B2 (https=) |
| EP (4) | EP2878339A1 (https=) |
| JP (2) | JP6595475B2 (https=) |
| KR (1) | KR102386815B1 (https=) |
| CN (1) | CN106232182B (https=) |
| AU (1) | AU2014359489B2 (https=) |
| CA (1) | CA2932218C (https=) |
| EA (1) | EA034218B1 (https=) |
| NZ (1) | NZ721802A (https=) |
| UA (1) | UA117154C2 (https=) |
| WO (1) | WO2015082357A1 (https=) |
| ZA (1) | ZA201604490B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| KR102131677B1 (ko) | 2018-03-20 | 2020-08-05 | 주식회사 아하 | 가이드 모듈 및 하폐수 처리용 산기장치 |
| US12110299B2 (en) * | 2018-09-17 | 2024-10-08 | Yungjin Pharm. Co., Ltd. | Thiazole derivatives and pharmaceutically acceptable salts thereof |
| WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| WO2022079290A2 (en) * | 2020-10-16 | 2022-04-21 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Cullin ring ubiquitin ligase compounds and uses thereof |
| WO2023275796A1 (en) * | 2021-07-01 | 2023-01-05 | Novartis Ag | Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors |
| CN119562812A (zh) * | 2022-07-05 | 2025-03-04 | 奥里吉恩肿瘤学有限公司 | 作为cdk12/13抑制剂的取代的n-(吡啶-2-基)乙酰胺衍生物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| JP2001501951A (ja) | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| NZ518376A (en) | 1999-11-18 | 2004-01-30 | Novartis Ag | Pesticidal aminoheterocyclamide compounds |
| KR100502033B1 (ko) | 2000-05-03 | 2005-07-25 | 에프. 호프만-라 로슈 아게 | 알키닐 페닐 헤테로방향족 글루코키나제 활성제 |
| JP4742333B2 (ja) | 2000-11-13 | 2011-08-10 | 日本農薬株式会社 | Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| WO2002046173A1 (en) | 2000-12-06 | 2002-06-13 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| WO2003020313A1 (en) * | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| WO2003055482A1 (en) * | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| EP1501815B1 (en) | 2002-04-26 | 2006-11-22 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| WO2004072066A1 (en) * | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| CA2551611C (en) * | 2003-12-26 | 2013-06-25 | Kyowa Kirin Co., Ltd. | Thiazole derivatives for treating or preventing parkinson's disease |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| CN101137631A (zh) | 2004-12-03 | 2008-03-05 | 转化技术制药公司 | 杂芳族葡糖激酶激活剂 |
| US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| CA2621227A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| US8546452B2 (en) * | 2005-10-12 | 2013-10-01 | Toa Eiyo Ltd. | S1P3 receptor antagonist |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2856037C (en) | 2005-12-28 | 2017-03-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008119734A2 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
| US8563594B2 (en) * | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| AU2008256937A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| AU2009205070A1 (en) | 2008-01-18 | 2009-07-23 | Astellas Pharma Inc. | Phenyl acetamide derivative |
| EP2265585B1 (en) | 2008-02-21 | 2014-09-17 | Boehringer Ingelheim International GmbH | Amine and ether compounds which modulate the cb2 receptor |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| KR101258331B1 (ko) | 2008-09-11 | 2013-04-26 | 화이자 인코포레이티드 | 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도 |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| WO2011008475A1 (en) * | 2009-06-30 | 2011-01-20 | Allergan, Inc. | Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases |
| US8168795B2 (en) * | 2009-08-11 | 2012-05-01 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011133734A1 (en) * | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| US9073895B2 (en) * | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| WO2013158939A1 (en) * | 2012-04-18 | 2013-10-24 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
-
2013
- 2013-12-02 EP EP13195372.1A patent/EP2878339A1/en not_active Withdrawn
-
2014
- 2014-11-28 KR KR1020167017929A patent/KR102386815B1/ko active Active
- 2014-11-28 EA EA201691160A patent/EA034218B1/ru not_active IP Right Cessation
- 2014-11-28 WO PCT/EP2014/075986 patent/WO2015082357A1/en not_active Ceased
- 2014-11-28 EP EP14811790.6A patent/EP3086845B1/en active Active
- 2014-11-28 JP JP2016536883A patent/JP6595475B2/ja active Active
- 2014-11-28 EP EP21155292.2A patent/EP3896068A1/en not_active Withdrawn
- 2014-11-28 UA UAA201607137A patent/UA117154C2/uk unknown
- 2014-11-28 US US15/100,326 patent/US9951017B2/en active Active
- 2014-11-28 NZ NZ721802A patent/NZ721802A/en unknown
- 2014-11-28 CA CA2932218A patent/CA2932218C/en active Active
- 2014-11-28 EP EP19210115.2A patent/EP3689864A1/en not_active Withdrawn
- 2014-11-28 CN CN201480074769.6A patent/CN106232182B/zh active Active
- 2014-11-28 AU AU2014359489A patent/AU2014359489B2/en active Active
-
2016
- 2016-07-01 ZA ZA201604490A patent/ZA201604490B/en unknown
-
2018
- 2018-03-16 US US15/923,837 patent/US20180201582A1/en not_active Abandoned
-
2019
- 2019-09-26 JP JP2019175781A patent/JP2020023512A/ja active Pending
-
2020
- 2020-01-24 US US16/751,472 patent/US11472772B2/en active Active
-
2022
- 2022-08-03 US US17/880,577 patent/US20220402875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020023512A (ja) | 2020-02-13 |
| JP2016539174A (ja) | 2016-12-15 |
| EA034218B1 (ru) | 2020-01-17 |
| EP3086845B1 (en) | 2019-11-20 |
| US20160297762A1 (en) | 2016-10-13 |
| EP3689864A1 (en) | 2020-08-05 |
| EP3896068A1 (en) | 2021-10-20 |
| EP2878339A1 (en) | 2015-06-03 |
| EP3086845A1 (en) | 2016-11-02 |
| US20180201582A1 (en) | 2018-07-19 |
| US20200157052A1 (en) | 2020-05-21 |
| UA117154C2 (uk) | 2018-06-25 |
| CN106232182A (zh) | 2016-12-14 |
| US11472772B2 (en) | 2022-10-18 |
| JP6595475B2 (ja) | 2019-10-23 |
| KR20160093710A (ko) | 2016-08-08 |
| EA201691160A1 (ru) | 2016-11-30 |
| NZ721802A (en) | 2022-04-29 |
| CN106232182B (zh) | 2019-11-01 |
| CA2932218C (en) | 2023-10-03 |
| AU2014359489B2 (en) | 2020-01-30 |
| US20220402875A1 (en) | 2022-12-22 |
| KR102386815B1 (ko) | 2022-04-14 |
| HK1226017A1 (en) | 2017-09-22 |
| US9951017B2 (en) | 2018-04-24 |
| WO2015082357A1 (en) | 2015-06-11 |
| CA2932218A1 (en) | 2015-06-11 |
| AU2014359489A1 (en) | 2016-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3088517T5 (en) | Humant anti-il-33-neutraliserende monoklonalt antistof | |
| DK3354246T3 (en) | Udstyrsmonteringssystem | |
| IL240606A0 (en) | New polypeptides | |
| GB201305668D0 (en) | Avs6 Integrin Antagonists | |
| GB201305825D0 (en) | New use | |
| HUE047186T2 (hu) | Új alkalmazás | |
| ZA201604295B (en) | Transduction | |
| IL240348A0 (en) | Transmuted imidazopyridines | |
| ZA201604490B (en) | S1p3 antagonists | |
| ZA201600275B (en) | Substituted pyrazolo-pyridinamines | |
| IL246271A0 (en) | Converted piperidinyl-tetrahydroquinolines | |
| HUP1300139A2 (en) | Phenoxypiperidine h3 antagonists | |
| GB201321922D0 (en) | Constructions | |
| GB201307510D0 (en) | Anchor | |
| AU353643S (en) | Stamphousing | |
| GB2516432B (en) | Head set | |
| GB201311130D0 (en) | Greensleeves I | |
| GB201306901D0 (en) | Combination | |
| ZA201506407B (en) | New polypeptides | |
| EP3014557A4 (en) | TELEPHONE ON FILE | |
| GB201321332D0 (en) | Fitting | |
| GB201301159D0 (en) | Head | |
| DK2989854T3 (en) | Strømstyret opvarmningssystem | |
| GB201304105D0 (en) | Agonist | |
| GB201320101D0 (en) | Nails |